Although Apple's review process for iPhone apps seems to elude most developers, some help is in sight. In addition to the FCC's ongoing investigations since Google Voice was rejected by Apple, a very useful Web site was recently created to publicize the details of such rejections.

The first paragraph in the New York Times story said it all: "The Drug Enforcement Administration has classified as controlled substances three steroids that are marketed as dietary supplements, but an antidoping official warned that new steroids have taken their place on the shelves of nutrition stores."

A dispute in Canada has brought light to an emerging privacy issue over the use of Facebook photos. Nathalie Blanchard's insurance company cut her disability benefits after their agent found photos of her on vacation through Facebook. 

Section 102(b) of the U.S. Patent Act prevents an inventor from getting a patent for an invention that was “described in a printed publication in this .

David Frum recently laid into the nutritional supplement industry with a guest commentary on CNN.com. The resident fellow at the American Enterprise Institute and one-time special assistant to President George W.

Several important apps developers are unhappy with Apple and the way the company is still exerting too much control over their App Store. Some developers are so frustrated with Apple and their stringent policies that they are completely halting iPhone development.

The headline in the Wall Street Journal read, "New Study Gives B Vitamin a Boost" and the first sentence in the article was, "Bring out the niacin."

While it may seem like an innocent act, a virtual poke on Facebook could have real-world legal implications.  A Tennessee court has held that a Facebook poke violated a protective order and is considered a communication with an opposing party.

A new app has been developed for the iPhone that connects people's faces to their names by using photos from their LinkedIn accounts.  The app is called Learn That Name.

Two days of hearings before the FDA about search-based advertising for drugs produced one possible solution: fixed warnings for products. Google has proposed that its AdWords could include a hyper-linked line that warns consumers about the potential dangers of a drug.